ArticleWorld journal of gastrointestinal surgery2026
Individual chemotherapy for patients colorectal cancer based on patient-derived tumor-like cell clusters.
Article in World journal of gastrointestinal surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is among the most common malignant tumors. Chemotherapy remains central to CRC management, yet many patients still fail to derive optimal benefit. Patient-derived tumor-like cell clusters (PTCs), a preclinical three-dimensional tumor model containing primary epithelial cells, fibroblasts, and immune cells, can more accurately predict drug efficacy because they closely resemble the original tumor tissue.
aimTo evaluate the feasibility of using PTCs to guide personalized chemotherapy for patients with CRC.
methodsFresh tumor tissues from 54 patients with resectable CRC were used to establish PTCs. Culture duration, diameter, and morphology were monitored. Hematoxylin-eosin staining was performed to assess PTC morphology. Drug sensitivity was evaluated through the PTC drug assay.
resultsPTCs exhibited inter- and intrapatient variability in growth rate, diameter, and morphology. Comparable proportions of PTCs showed strong or effective inhibition in response to FOLFOX and FOLFIRI. FOLFOXIRI demonstrated robust antitumor activity in 97% of PTC models. However, responses to FOLFOX and FOLFIRI varied considerably among individuals. FOLFOXIRI showed cell-killing activity similar to FOLFOX or FOLFIRI.
conclusionAccounting for patient's pathological and clinical characteristics, PTC-based drug-sensitivity testing can help accurately identify effective agents for CRC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.